PMV Pharmaceuticals saw the highest growth of 0.99% in patent filings and 0.49% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of PMV Pharmaceuticals’s patent filings and grants. Buy the databook here.
PMV Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where PMV Pharmaceuticals is filings its patents. Among the top granted patent authorities, PMV Pharmaceuticals has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for PMV Pharmaceuticals
Patents related to rare diseases lead PMV Pharmaceuticals's portfolio
PMV Pharmaceuticals has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead PMV Pharmaceuticals portfolio followed by lung cancer, and lymphoma
PMV Pharmaceuticals has highest number of patents in breast cancer followed by lung cancer, lymphoma, bone sarcoma, and ewing sarcoma. For breast cancer, nearly 8% of patents were filed and 50% of patents were granted in Q2 2024.
For comprehensive analysis of PMV Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.